Kraft Foods has come up short in its high-stakes legal battle against Bega over the right to use its distinctive peanut butter trade dress in Australia, allowing Bega to maintain its hold on the $60 million per year stake in the peanut butter market which it acquired by purchasing Kraft unit Mondelez’s Australian and New Zealand business in 2017.
A Netherlands-based fashion company is challenging a decision by IP Australia to refuse a trade mark for its brand of high-end menswear named after the father of the modern Olympic Games.
Judgment is expected Wednesday in a high-stakes dispute between consumer giants Kraft and Bega over who owns the rights to the signature Kraft peanut butter trade dress in Australia.
German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
The consumer regulator has dragged Western Australia’s Quantum Housing and its sole director to court for allegedly engaging in unconscionable conduct and false, misleading or deceptive conduct in relation to a government-sponsored affordable housing program that incentivises below-market rentals.
Nine Network has been ordered to pay a British tourist $100,000 in a defamation suit over a news broadcast that aired following his acquittal on assault charges related to a brawl with rugby player that used the term “coward punch” to describe the dust-up.
The Australian Securities and Investments Commission has won its bid for a court order placing Melbourne-based forex trader Berndale Capital into receivership for allegedly failing to safeguard client money.
Two units of private equity company Antin Infrastructure Partners have taken their legal battle with Spain to Australian court, filing a lawsuit to enforce a $161 million arbitration award related to investments the companies made in two solar plants in southern Spain.
Building products supplier Wagners has taken its largest cement customer, Boral, to court in a dispute over pricing, and will take a $10 million hit to its 2019 earnings as a result.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker’s plans to market a competing insulin injector pen in Australia.